Optimal investment in HIV prevention programs: more is not always better
- 13 August 2008
- journal article
- research article
- Published by Springer Nature in Health Care Management Science
- Vol. 12 (1) , 27-37
Abstract
This paper develops a mathematical/economic framework to address the following question: Given a particular population, a specific HIV prevention program, and a fixed amount of funds that could be invested in the program, how much money should be invested? We consider the impact of investment in a prevention program on the HIV sufficient contact rate (defined via production functions that describe the change in the sufficient contact rate as a function of expenditure on a prevention program), and the impact of changes in the sufficient contact rate on the spread of HIV (via an epidemic model). In general, the cost per HIV infection averted is not constant as the level of investment changes, so the fact that some investment in a program is cost effective does not mean that more investment in the program is cost effective. Our framework provides a formal means for determining how the cost per infection averted changes with the level of expenditure. We can use this information as follows: When the program has decreasing marginal cost per infection averted (which occurs, for example, with a growing epidemic and a prevention program with increasing returns to scale), it is optimal either to spend nothing on the program or to spend the entire budget. When the program has increasing marginal cost per infection averted (which occurs, for example, with a shrinking epidemic and a prevention program with decreasing returns to scale), it may be optimal to spend some but not all of the budget. The amount that should be spent depends on both the rate of disease spread and the production function for the prevention program. We illustrate our ideas with two examples: that of a needle exchange program, and that of a methadone maintenance program.Keywords
This publication has 45 references indexed in Scilit:
- Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled TrialClinical Infectious Diseases, 2007
- HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countriesBMC Health Services Research, 2007
- Optimal mix of screening and contact tracing for endemic diseasesMathematical Biosciences, 2007
- A cost function for HIV prevention services: is there a 'u' – shape?Cost Effectiveness and Resource Allocation, 2007
- Cost-Effectiveness of Male Circumcision for HIV Prevention in a South African SettingPLOS Medicine, 2006
- Directly Administered Antiretroviral Therapy in an Urban Methadone Maintenance Clinic: A Nonrandomized Comparative StudyClinical Infectious Diseases, 2004
- Interpretation of cost-effectiveness analysesJournal of General Internal Medicine, 1998
- Prevention of mother-to-child transmission of HIV-1 infectionAIDS, 1998
- Threshold Analysis and Programs for Prevention of HIV InfectionMedical Decision Making, 1995
- HIV seroconversion in intravenous drug users in San Francisco, 1985–1990AIDS, 1994